Aquamarine Financial (Cayman) Ltd has recently amended its Schedule 13G, indicating a notable increase in its stake in Oramed Pharmaceuticals Inc. The filing reveals that Aquamarine now holds 2,653,567 shares, representing 6.38% of Oramed's common stock. This strategic move underscores Aquamarine's commitment to its investment in the pharmaceutical sector.

Oramed Pharmaceuticals Inc., based in New York, specializes in pharmaceutical preparations, focusing on innovative treatments. This recent filing, dated November 13, 2026, is part of a series of disclosures made by Aquamarine Financial, showcasing its ongoing interest in Oramed.

Background

Aquamarine Financial (Cayman) Ltd is a company incorporated in the Cayman Islands. The company has recently been active in filing various forms with the SEC, including multiple Schedule 13G filings. The current filing, accession number 0001493152-26-051853, is an amendment to a previous Schedule 13G, reflecting changes in its beneficial ownership of Oramed Pharmaceuticals.

What the Filing Says

The amended filing states, "Aquamarine Financial (Cayman) Ltd now beneficially owns 2,653,567 shares of Oramed Pharmaceuticals, equating to 6.38% of the total shares outstanding." This adjustment in ownership percentage is significant as it indicates Aquamarine's growing influence in Oramed.

Impact

This development may affect various stakeholders in the pharmaceutical industry, particularly those involved with Oramed Pharmaceuticals. As Aquamarine increases its stake, it may influence Oramed's strategic decisions and market performance. The filing also highlights the competitive landscape in the pharmaceutical preparations sector, where investment stakes can lead to shifts in control and direction.

What's Next

The filing does not specify what happens next regarding Aquamarine's investment strategy or any potential actions related to its stake in Oramed Pharmaceuticals.